OBJECTIVE: The diagnosis and treatment of youth with severe nonepisodic irritability and hyperarousal, a syndrome defined as severe mood dysregulation (SMD) by Leibenluft, has been the focus of increasing concern. We conducted the first randomized double-blind, placebo-controlled trial in SMD youth, choosing lithium on the basis of its potential in treating irritability and aggression and neuro-metabolic effects. METHODS:SMD youths 7-17 years were tapered off their medications. Those who continued to meet SMD criteria after a 2-week, single-blind, placebo run-in were randomized to a 6-week double-blind trial of either lithium (n = 14) or placebo (n = 11). Clinical outcome measures were: (1) Clinical Global Impressions-Improvement (CGI-I) score less than 4 at trial's end and (2) the Positive and Negative Syndrome Scale (PANSS) factor 4 score. Magnetic resonance spectroscopy (MRS) outcome measures were myoinositol (mI), N-acetyl-aspartate (NAA), and combined glutamate/glutamine (GLX), all referenced to creatine (Cr). RESULTS: In all, 45% (n = 20/45) of SMD youths were not randomized due to significant clinical improvement during the placebo run-in. Among randomized patients, there were no significant between-group differences in either clinical or MRS outcome measures. CONCLUSION: Our study suggests that although lithium may not result in significant clinical or neurometabolic alterations in SMD youths, further SMD treatment trials are warranted given its prevalence.
RCT Entities:
OBJECTIVE: The diagnosis and treatment of youth with severe nonepisodic irritability and hyperarousal, a syndrome defined as severe mood dysregulation (SMD) by Leibenluft, has been the focus of increasing concern. We conducted the first randomized double-blind, placebo-controlled trial in SMD youth, choosing lithium on the basis of its potential in treating irritability and aggression and neuro-metabolic effects. METHODS: SMD youths 7-17 years were tapered off their medications. Those who continued to meet SMD criteria after a 2-week, single-blind, placebo run-in were randomized to a 6-week double-blind trial of either lithium (n = 14) or placebo (n = 11). Clinical outcome measures were: (1) Clinical Global Impressions-Improvement (CGI-I) score less than 4 at trial's end and (2) the Positive and Negative Syndrome Scale (PANSS) factor 4 score. Magnetic resonance spectroscopy (MRS) outcome measures were myoinositol (mI), N-acetyl-aspartate (NAA), and combined glutamate/glutamine (GLX), all referenced to creatine (Cr). RESULTS: In all, 45% (n = 20/45) of SMD youths were not randomized due to significant clinical improvement during the placebo run-in. Among randomized patients, there were no significant between-group differences in either clinical or MRS outcome measures. CONCLUSION: Our study suggests that although lithium may not result in significant clinical or neurometabolic alterations in SMD youths, further SMD treatment trials are warranted given its prevalence.
Authors: Peter H Silverstone; Ren H Wu; Tina O'Donnell; Michele Ulrich; Sheila J Asghar; Christopher C Hanstock Journal: Hum Psychopharmacol Date: 2002-10 Impact factor: 1.672
Authors: Daniel F Connor; Stephen J Glatt; Ivan D Lopez; Denise Jackson; Richard H Melloni Journal: J Am Acad Child Adolesc Psychiatry Date: 2002-03 Impact factor: 8.829
Authors: Peter H Silverstone; Ren H Wu; Tina O'Donnell; Michele Ulrich; Sheila J Asghar; Christopher C Hanstock Journal: Int Clin Psychopharmacol Date: 2003-03 Impact factor: 1.659
Authors: Ellen Leibenluft; Dennis S Charney; Kenneth E Towbin; Robinder K Bhangoo; Daniel S Pine Journal: Am J Psychiatry Date: 2003-03 Impact factor: 18.112
Authors: Boris Birmaher; David A Axelson; Kelly Monk; Catherine Kalas; Duncan B Clark; Mary Ehmann; Jeffery Bridge; Jungeun Heo; David A Brent Journal: J Am Acad Child Adolesc Psychiatry Date: 2003-04 Impact factor: 8.829
Authors: Melissa P Delbello; Michael L Schwiers; H Lee Rosenberg; Stephen M Strakowski Journal: J Am Acad Child Adolesc Psychiatry Date: 2002-10 Impact factor: 8.829
Authors: Constance M Moore; Christina M Demopulos; Michael E Henry; Ronald J Steingard; Linda Zamvil; Alain Katic; Janis L Breeze; JoEllyn C Moore; Bruce M Cohen; Perry F Renshaw Journal: Am J Psychiatry Date: 2002-07 Impact factor: 18.112
Authors: James T McCracken; James McGough; Bhavik Shah; Pegeen Cronin; Daniel Hong; Michael G Aman; L Eugene Arnold; Ronald Lindsay; Patricia Nash; Jill Hollway; Christopher J McDougle; David Posey; Naomi Swiezy; Arlene Kohn; Lawrence Scahill; Andres Martin; Kathleen Koenig; Fred Volkmar; Deirdre Carroll; Allison Lancor; Elaine Tierney; Jaswinder Ghuman; Nilda M Gonzalez; Marco Grados; Benedetto Vitiello; Louise Ritz; Mark Davies; James Robinson; Don McMahon Journal: N Engl J Med Date: 2002-08-01 Impact factor: 91.245
Authors: Garrett M Sparks; David A Axelson; Haifeng Yu; Wonho Ha; Javier Ballester; Rasim S Diler; Benjamin Goldstein; Tina Goldstein; Mary Beth Hickey; Cecile D Ladouceur; Kelly Monk; Dara Sakolsky; Boris Birmaher Journal: J Am Acad Child Adolesc Psychiatry Date: 2014-01-26 Impact factor: 8.829
Authors: James G Waxmonsky; Daniel A Waschbusch; Peter Belin; Tan Li; Lysett Babocsai; Hugh Humphery; Meaghan E Pariseau; Dara E Babinski; Martin T Hoffman; Jenifer L Haak; Jessica R Mazzant; Gregory A Fabiano; Jeremy W Pettit; Negar Fallahazad; William E Pelham Journal: J Am Acad Child Adolesc Psychiatry Date: 2015-12-28 Impact factor: 8.829
Authors: Karen E Seymour; Richard N Jones; Grace K Cushman; Thania Galvan; Megan E Puzia; Kerri L Kim; Anthony Spirito; Daniel P Dickstein Journal: Eur Child Adolesc Psychiatry Date: 2015-06-06 Impact factor: 4.785
Authors: C I Giakoumatos; P Nanda; I T Mathew; N Tandon; J Shah; J R Bishop; B A Clementz; G D Pearlson; J A Sweeney; C A Tamminga; M S Keshavan Journal: J Psychiatr Res Date: 2014-12-23 Impact factor: 4.791
Authors: Simone P Haller; Katharina Kircanski; Argyris Stringaris; Michal Clayton; Hong Bui; Courtney Agorsor; Sofia I Cardenas; Kenneth E Towbin; Daniel S Pine; Ellen Leibenluft; Melissa A Brotman Journal: Behav Ther Date: 2019-11-27
Authors: D G Kondo; T L Hellem; X-F Shi; Y H Sung; A P Prescot; T S Kim; R S Huber; L N Forrest; P F Renshaw Journal: AJNR Am J Neuroradiol Date: 2014-02-20 Impact factor: 3.825